王者荣耀kpl外围投注IQVIA Biotech UK会议2019年的见解
在资金，创新，政策和商业化方面，英国及以后的生物技术状况是什么？欧洲思想领导人的莎拉·里克伍德（Sarah Rickwood）于11月7日在IQVIA Biotech会议上主持了一个小组，在金融家，政策制定者，生物技术企业家和科学家参加的一次会议上。本文总结了从所有参与者的洞察力的一天中的一些关键主题，对“国家状态”提供了独特的见解，不仅是英国生物技术，而且还提供了超越。王者荣耀kpl外围投注
这一天讨论了推动整个创新引擎的资金，投资银行家和投资者从杰弗里斯国际，来自普罗兰特的英国和丹·曼哈州的Catrin Dilloway，在Martin Turner演示文稿之后，来自Polar Capital的Catrin Dilloway。of the UK’s BioIndustry Association. The focus of discussion was on what makes investors invest. All panellists agreed that scientific innovation alone, however, novel and strong, was insufficient to attract investors. Start-ups need a realistic and clear business plan that addresses the eventual commercial realities likely for the eventual product, including the payer perspective and market access environment. Founders of start-ups, often experts steeped in the basic research, will have much to learn about the realities of the commercial and real-world environment in which their ideas will bear fruit. They may have to take the tough decision to stand aside for a business-focused CEO as their company transitions to launch preparation mode. They will certainly need to take on board external advice and support as their product becomes a commercial reality.
创新正在支持开发新方法，从未以前改善健康。lol买外围用什么软件这几天的Biotech的一个关键主题是创新不仅仅是在分子中 - 它在建立的数据中，以帮助识别未满足的需求，定义患者人口，速度试验和评估产品。英国是一个全球热点，用于开发强大，质量和链接的患者数据，以规模开发。下届会议提供了洞察力，进入基因组，更广泛的医疗保健系王者荣耀kpl外围投注统和癌症特异性竞技场的举措。lol买外围用什么软件将塞维亚的基因组学队伍将在E360平台上具有重大战略合作，为选择遗传支持的目标或适应症进行了重大的战略合作，这使得临床发展的成功率增加了潜力。Interest in the clinical applications of genomics data has grown rapidly among big Pharma, for example GSK’s partnership with the private genomics firm 23andMe, but it is also possible for Biotechs to work with one of the world’s largest and highest quality genomics database, the over 100,000 genomes collected by Genomics England. This database possesses breadth (115,000+ genomes sequenced so far), depth, as these are full genomes that are sequenced rather than the snippets (SNPs in genomics terms) collected by genotyping databases, and, crucially, linkage, to other elements of patient data such as health records and pathology data as well as prescribing data in the near future, which provide the context that is vital for true insights and medical breakthroughs. Will looked forward to the next UK target of 5 million fully sequenced genomes analyses, which will usher in a step change in the utility of genomics to clinical research and development.
英国的生命科学产业战略举措也激发了英国国家健康数据科学研究所的创造。lol买外围用什么软件本戈登概述了自2018年4月自2018年4月以来，这一新组织将如何运作，并将创建一个世界领先的健康数据基础架构，它在众多筒仓中加入点，其中产生了有价值的健康数据。lol买外围用什么软件
这样做的一种方法是通过七个健康数据研究数据集线器为英国，重点聚焦特定的疾病区域或实际证据等特定学lol买外围用什么软件科。IQVIA.’s Yosh Cook and Dr Charlie Davie, the DATA-CAN hub Director, outlined how the hub focused around Cancer will work, and IQVIA’s role as one of the hub’s partners to deliver the vision to enable access to high quality data on cancer available for research, improved care delivery and clinical study.
第三届会议证明了一场艰难的人，因为它提供了最必要和最具挑战性的患者和付款人的声音。在医疗保健行业会议上听取患者和患者倡导者的声音，脑癌倡导网络Braintrust的Helen Bulbeck博士始终是一种非常有价值的经验，为患有脑癌患者的生活提供了强大的窗口。lol买外围用什么软件她说明了为什么患者应在创新的市场之旅中开始而不是终点，并为患者参与成功提供有关DOS和DOS的务实建议。
IQVIA的证据基础和全球对英国背景的看法为下一次会议提供了一个很好的起点 - 友好但强大的思想和观点交流了IQVIA的Angela McFarlane和NHS England England的商业药品主管Blake Dark之间对创新药品的吸收和资助。Angela laid out the challenges and opportunities of the UK market for pharma, highlighting the great work that’s been done to keep the funding and uptake of innovation at the forefront of the medicines agenda, as well as outlining the areas where much work still needs to be done. Blake was unfortunately constrained in his remarks by the strictures of election purdah, but even with these constraints gave a fascinating and sympathetic insight into the way in which NHS England thinks when making access and funding decisions – invaluable intelligence for Biotech companies starting their journey to market access understanding and success.
最后，生物技术之旅进入了商业化。伊克维亚（Iqvia）的莎拉·里克伍德（Sarah Rickwood）为为什么生物技术公司从来没有更好的时机将自己的创新商业化了 - 迅速的听众发现，他们压倒性地同意了她的同意。伊克维亚（Iqvia）的安迪·波特（Andy Pollpeter）对国际看法进行了国际观点，讨论了美国所有人最大的生物技术奖的挑战：美国市场。
细胞和基因治疗弹射博士的麦克尔贝内特博士，通过细胞和基因治疗公司面临的制造挑战的迷人概述，以及如何汇集制造设施和制造业和发展专业知识的汇集方法对于这些高度至关重要经过复杂的疗法，商品成本是一个主要的考虑因素，以及创造和提供疗法的物流与之前的Pharma公司面临的任何挑战不同。
Iain McGill, the CEO of Quell Therapeutics provided knowledgeable compering and summary of each session throughout the day, and the audience provided a stream of relevant and engaging questions, as well as extremely positive feedback on the event, specifically praising IQVIA’s outreach and relevance to smaller start up and biotech organisations.